| 1. |
|
|
| 2. |
- Erickson, ML, et al.
(author)
-
Understanding heterogeneity of responses to, and optimizing clinical efficacy of, exercise training in older adults: NIH NIA Workshop summary
- 2023
-
In: GeroScience. - : Springer Science and Business Media LLC. - 2509-2723 .- 2509-2715. ; 45:21, s. 569-589
-
Journal article (peer-reviewed)abstract
- Exercise is a cornerstone of preventive medicine and a promising strategy to intervene on the biology of aging. Variation in the response to exercise is a widely accepted concept that dates back to the 1980s with classic genetic studies identifying sequence variations as modifiers of the VO2max response to training. Since that time, the literature of exercise response variance has been populated with retrospective analyses of existing datasets that are limited by a lack of statistical power from technical error of the measurements and small sample sizes, as well as diffuse outcomes, very few of which have included older adults. Prospective studies that are appropriately designed to interrogate exercise response variation in key outcomes identified a priori and inclusive of individuals over the age of 70 are long overdue. Understanding the underlying intrinsic (e.g., genetics and epigenetics) and extrinsic (e.g., medication use, diet, chronic disease) factors that determine robust versus poor responses to various exercise factors will be used to improve exercise prescription to target the pillars of aging and optimize the clinical efficacy of exercise training in older adults. This review summarizes the proceedings of the NIA-sponsored workshop entitled, “Understanding Heterogeneity of Responses to, and Optimizing Clinical Efficacy of, Exercise Training in Older Adults” and highlights the importance and current state of exercise response variation research, particularly in older adults, prevailing challenges, and future directions.
|
|
| 3. |
|
|
| 4. |
- Nader, GA, et al.
(author)
-
Intracellular signaling specificity in skeletal muscle in response to different modes of exercise
- 2001
-
In: Journal of applied physiology (Bethesda, Md. : 1985). - : American Physiological Society. - 8750-7587 .- 1522-1601. ; 90:5, s. 1936-1942
-
Journal article (peer-reviewed)abstract
- The aim of this study was to understand better the specific signaling events resulting from different modes of exercise. Three different exercise protocols were employed based on their well-characterized, long-term training effects on either muscle hypertrophy or endurance phenotypes. Rats were subjected to a single bout of either a high-frequency electrical stimulation, a low-frequency electrical stimulation, or a running exercise protocol. Postexercise intracellular signaling was analyzed in the tibialis anterior and soleus muscles at 0, 3, and 6 h. A prolonged increase in p70S6k and a transient increase in protein kinase B phosphorylation were only observed in response to a growth-inducing stimulus (e.g., tibialis anterior in high-frequency electrical stimulation). In contrast, extracellular regulated kinase and 38-kDa stress-activated protein kinase were activated in response to all forms of exercise at 0 h, but only extracellular regulated kinase phosphorylation was found significantly elevated at 6 h after running exercise. These results demonstrate that different exercise protocols resulted in the selective activation of specific intracellular signaling pathways, which may determine the specific adaptations induced by different forms of exercise.
|
|
| 5. |
- Nader, GA, et al.
(author)
-
mTOR function in skeletal muscle hypertrophy: increased ribosomal RNA via cell cycle regulators
- 2005
-
In: American journal of physiology. Cell physiology. - : American Physiological Society. - 0363-6143 .- 1522-1563. ; 289:6, s. C1457-C1465
-
Journal article (peer-reviewed)abstract
- The purpose of this study was to identify the potential downstream functions associated with mammalian target of rapamycin (mTOR) signaling during myotube hypertrophy. Terminally differentiated myotubes were serum stimulated for 3, 6, 12, 24, and 48 h. This treatment resulted in significant myotube hypertrophy (protein/DNA) and increased RNA content (RNA/DNA) with no changes in DNA content or indices of cell proliferation. During myotube hypertrophy, the increase in RNA content was accompanied by an increase in tumor suppressor protein retinoblastoma (Rb) phosphorylation and a corresponding increase in the availability of the ribosomal DNA transcription factor upstream binding factor (UBF). Serum stimulation also induced an increase in cyclin D1 protein expression in the differentiated myotubes with a concomitant increase in cyclin D1-dependent cyclin-dependent kinase (CDK)-4 activity toward Rb. The increases in myotube hypertrophy and RNA content were blocked by rapamycin treatment, which also prevented the increase in cyclin D1 protein expression, CDK-4 activity, Rb phosphorylation, and the increase in UBF availability. Our findings demonstrate that activation of mTOR is necessary for myotube hypertrophy and suggest that the role of mTOR is in part to modulate cyclin D1-dependent CDK-4 activity in the regulation of Rb and ribosomal RNA synthesis. On the basis of these results, we propose that common molecular mechanisms contribute to the regulation of myotube hypertrophy and growth during the G1phase of the cell cycle.
|
|
| 6. |
|
|
| 7. |
- Villa, LL, et al.
(author)
-
Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial
- 2005
-
In: The Lancet Oncology. - 1474-5488 .- 1470-2045. ; 6:5, s. 271-278
-
Journal article (peer-reviewed)abstract
- Background A randomised double-blind placebo-controlled phase II study was done to assess the efficacy of a prophylactic quadrivalent vaccine targeting the human papillomavirus (HPV) types associated with 70% of cervical cancers (types 16 and 18) and with 90% of genital warts (types 6 and 11). Methods 277 young women (mean age 20.2 years [SD 1.7]) were randomly assigned to quadrivalent HPV (20 μ g type 6, 40 μ g type 11, 40 μ g type 16, and 20 μ g type 18) L1 virus-like-particle (VLP) vaccine and 275 (mean age 20.0 years [1.7]) to one of two placebo preparations at day 1, month 2, and month 6. For 36 months, participants underwent regular gynaecological examinations, cervicovaginal sampling for HPV DNA, testing for serum antibodies to HPV, and Pap testing. The primary endpoint was the combined incidence of infection with HPV 6, 11, 16, or 18, or cervical or external genital disease (ie, persistent HPV infection, HPV detection at the last recorded visit, cervical intraepithelial neoplasia, cervical cancer, or external genital lesions caused by the HPV types in the vaccine). Main analyses were done per protocol. Findings Combined incidence of persistent infection or disease with HPV 6, 11, 16, or 18 fell by 90% (95% CI 71-97, p< 0.0001) in those assigned vaccine compared with those assigned placebo. Interpretation A vaccine targeting HPV types 6, 11, 16, 18 could substantially reduce the acquisition of infection and clinical disease caused by common HPV types.
|
|
| 8. |
- Kanai, M, et al.
(author)
-
- 2023
-
swepub:Mat__t
|
|
